Direxion mRNA ETF

Frequently Asked Questions About MSGR

What does MSGR invest in?

The fund, under normal circumstances, invests at least 80% of its assets in the securities that comprise the index or investments with economic characteristics similar to the securities included in the index. The index provides exposure to the performance of companies, publicly listed in the United States, Canada and Europe, that are leading the development and application of messenger RNA (“mRNA”) technology. The fund is non-diversified.

What is the expense ratio of MSGR?

An expense ratio for Direxion mRNA ETF (MSGR) is not available from our data sources — neither our market-data feed nor the SEC's structured prospectus and annual-report datasets report one for this share class. The fund's prospectus on the issuer's site carries the authoritative fee.

How big is MSGR?

Direxion mRNA ETF (MSGR) manages $3.1M in total assets. AUM determines bid-ask liquidity and the fund's vulnerability to closure — funds below ~$50M are at higher risk of liquidation.

Is MSGR actively managed or an index fund?

MSGR's management style is described in the fund's prospectus. See the description on the Summary tab for the published strategy.

When was MSGR launched?

Direxion mRNA ETF (MSGR) launched in December 2021 and is managed by Direxion.

How has MSGR performed?

MSGR's total return — price change plus reinvested distributions — is charted at the top of this page. Switch the price chart to Total Return and pick a 1-year, 3-year, 5-year, or 10-year window to read the compound annual growth rate (CAGR) over each horizon.